Salts and crystalline forms of an ap2 associated kinase 1 inhibitor

Abstract

The present disclosure relates to pharmaceutically acceptable salts and crystalline forms of Compound 1, pharmaceutical compositions comprising the salts and crystalline forms of Compound 1, and their use in treating muscular diseases, such as Duchene Muscular Dystrophy (DMD), that are regulated by AAK1.

Dependencies are inferred from the claim text.